DCR

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 -
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 -

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 -

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 -
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 0.91 [0.63; 1.32], 1 RCT, I2=0%
inconclusive result